Drugmakers' shares fell globally after President Trump said he would [sign an executive order]( ...

Shares of pharmaceutical companies declined after U.S. President Donald Trump announced plans to lower U.S. prescription drug ...

England’s drug approval body has resisted pressure from pharmaceutical companies to loosen its process for recommending drugs and is pressing instead for the NHS to speed up the rollout of approved ...

The trial’s primary endpoint is pCR, with secondary endpoints including event-free survival (EFS), overall survival, safety, ...

A mineralocorticoid receptor antagonist that blocks excess aldosterone and reduces fluid volumes, spironolactone is the ...

Top decision-makers from across the biopharma ecosystem will convene in Chicago for the 2nd BioCentury Grand Rounds – U.S., at the intersection of research, investment and drug development. Designed ...

Enhertu delivered a phase 3 trial win in early-stage breast cancer. Takeda spotlighted three late-stage readouts as a ...

AstraZeneca and Daiichi Sankyo's anti-HER2 drug Enhertu has been shown to provide a benefit in a phase 3 trial in early-stage breast cancer for the first time, setting up regulatory filings.

Shares of Asia drugmakers fell on Monday after President Trump said he would sign an executive order aimed at lowering the cost of prescription drugs.

Shares of Asian pharmaceutical companies fell after US President Donald Trump said he planned to order a cut in US ...

President Trump's \"most favored nation\" policy aims to drastically lower U.S. prescription drug prices by aligning them ...